TradingMenu expanded
Forge Markets Browse Companies
DataMenu expanded
Forge Data Private Market Index IPO Stock Tracker
SolutionsMenu expanded
For Institutions For Shareholders For Investors For Companies In Europe
InsightsMenu expanded
All Insights Blog Glossary Reports Videos Webinars
Popular Topics
Buying Pre-IPO Shares Selling Pre-IPO Shares Private Market Updates Forge Investment Outlook Startup News
AboutMenu expanded
About Us Team Investor Relations People & Culture Careers FAQs
Log In Sign Up
Trading Menu expandedTrading
Forge Markets
Browse Companies
Data Menu expandedData
Forge Data
Private Market Index
IPO Stock Tracker
Solutions Menu expandedSolutions
For Institutions
For Shareholders
For Investors
For Companies
In Europe
Insights Menu expandedInsights
All Insights
Blog
Glossary
Reports
Videos
Webinars
Popular Topics
Buying Pre-IPO Shares
Selling Pre-IPO Shares
Private Market Updates
Forge Investment Outlook
Startup News
About Menu expandedAbout
About Us
Team
Investor Relations
People & Culture
Careers
FAQs
Trading / Browse Private Companies / Chroma Medicine Stock

Chroma Medicine Stock

chromamedicine.comHealthcare / BioTech & PharmaFounded: 2020Funding to Date: $262MM

Chroma Medicine leverages genomic medicine to develop therapeutics able to control gene expression. With the ability to target parts of the genome, the goal is relief for patients suffering from severe illnesses. Chroma Medicine was founded in 2021 by Angelo Lombardo Ph.D., Luigi Naldini Ph.D., David Liu Ph.D., and Jonathan Weissman Ph.D. and is headquartered in Boston, MA.

Buy or sell Chroma Medicine stockLearn more about Chroma Medicine IPO
Register for Details

For more details on financing and valuation for Chroma Medicine, register or login.

Please provide a valid email address.

By registering, you agree to Forge’s Terms of Use. Already registered? Log in

OverviewFinancingsValuation

Enterprise Value (based on primary financings)

Powered by Forge Data
Enterprise Value

View Enterprise Value for Chroma Medicine.

Register Today

Chroma Medicine investors also invested in these private companies

Atlas Venture
Arch Venture Partners
DCVC
Sofinnova Investments
Osage University Partners
Newpath Partners

Team

Management Team

Vic Myer Ph.D
Chief Scientific Officer & President
Brett Kaplan MD
Chief Financial and Strategy Officer & Chief Corporate Development Officer

Board Members

Bihua Chen
Cormorant Asset Management
George Golumbeski Ph.D
ARCH Venture Partners
John Maraganore Ph.D
ARCH Venture Partners
Thomas Cahill Ph.D
Newpath Partners

Other companies like Chroma Medicine in the BioTech & Pharma sector

ANDE

Sector
Healthcare / BioTech & Pharma
 
 

Altos Labs

Sector
Healthcare / BioTech & Pharma
Last Round Est. Valuation
$3.67B

Tempus

Sector
Healthcare / BioTech & Pharma
Last Round Est. Valuation
$8.45B

Life Biosciences

Sector
Healthcare / BioTech & Pharma
Last Round Est. Valuation
$500MM

Biosplice Therapeutics

Sector
Healthcare / BioTech & Pharma
 
 

Resilience

Sector
Healthcare / BioTech & Pharma
Last Round Est. Valuation
$8.84B

Pendulum Therapeutics

Sector
Healthcare / BioTech & Pharma
Last Round Est. Valuation
$303.94MM

Colossal Biosciences

Sector
Healthcare / BioTech & Pharma
Last Round Est. Valuation
$1.01B

Eikon Therapeutics

Sector
Healthcare / BioTech & Pharma
Last Round Est. Valuation
$4.74B

News Highlights

The Boston Globe 03/01/2023
Chroma Medicine raises $135 million for its epigenetic editing therapies
Chroma's approach, known as epigenetic editing, could have broad applications for treating both rare and common diseases.
FIERCE BIOTECH 02/28/2023
Chroma bags another 9-digit financing, taking $135M series B to bolster epigenetic-focused platform
A more cautious financing market is evidently no barrier for Chroma Medicine and its epigenetic-focused tech, with the Cambridge, Massachusetts-based biotech bagging $135 million in series B funds to build out its platform.
PR Newswire 09/20/2022
Chroma Medicine Announces Formation of Scientific Advisory Board of Global Experts in Gene Editing and Cell and Gene Therapy
Chroma Medicine, Inc., (Chroma) a genomic medicine company pioneering single-dose epigenetic editing therapeutics, today announced the formation of a Scientific Advisory Board (SAB) comprising renowned leaders in epigenetics, cell and gene therapy, and synthetic biology: Bradley Bernstein, M.D., Ph.D., Paula Cannon, Ph.D., Howard Chang, M.D., Ph.D., and Ahmad (Mo) Khalil, Ph.D.

Trending Companies

Frequently Asked Questions

Updated on: Sep 29, 2023